INTRODUCTION
Developmental and epileptic encephalopathies (DEEs) are a rare heterogeneous group of neurodevelopmental disorders, characterized by early-onset seizures that are often intractable, electroencephalographic abnormalities, developmental delay or regression, and various comorbidities [1-3]. Previous studies showed that one-third of children presenting with epilepsy before the age of three are medically intractable and 36% of epilepsy beginning before the age of two manifest as epileptic encephalopathy [4,5]. A growing number of genetically determined forms of DEEs have been identified over the past few decades [6]. The underlying genetic etiology is not only associated with frequent epileptic activity but also with a developmental delay because their onset coincides with crucial neurodevelopment [6,7]. Large-scale research has been uncovering numerous genes associated with DEEs, using chromosomal microarrays, whole exome sequencing (WES) and whole genome sequencing (WGS) [8,9]. However, the most thorough sequencing studies leave 60–65% of patients without a molecular diagnosis [9]. In contrast, in smaller studies of neonates and infants with epileptic encephalopathy, 80% or more of the patients had a genetic cause [10,11], which implicates the importance of patient selection and diagnostic methods. Here, we reviewed causative genes for early-onset DEEs including Ohtahara syndrome, early myoclonic encephalopathy (EME), epilepsy of infancy with migrating focal seizures (EIMFS), infantile spasms (West syndrome), and Dravet syndrome that start within the first year of life. The purpose of this review is to help increase recognition of early-onset DEEs and encourage the clinicians to start considering genetic testing as an important investigation along with an electroencephalogram for better understanding and management of DEEs.
AVAILABLE GENETIC TESTING AND DIAGNOSTIC YIELD
The first recognition of a genetic cause for an epileptic encephalopathy was in 2001, with the finding of de novo SCN1A variants in Dravet syndrome patients [12]. Genetic testing for DEEs includes karyotype, chromosomal microarray (CMA), single-gene sequencing, panel sequencing, whole exome sequencing, and whole genome sequencing. Karyotype may be useful in cases with dysmorphism, multi-organ involvement, and epilepsy and can help to identify rearrangements such as translocations, aneuploidy, or ring chromosome [13,14]. Diagnostic yield of karyotype remains unclear in DEEs. Copy number variation is an important molecular cause of epileptic encephalopathy, with the diagnostic yield from chromosomal microarray ranges from 5% to 16% [15-17]. Single gene sequencing may be useful when the phenotype suggests a specific syndrome such as Dravet syndrome, tuberous sclerosis complex, or GLUT-1 transporter defect [13,14]. The diagnostic yield of single gene sequencing depends on genes tested. When the clinical presentation is undifferentiated and there is phenotypic variability, gene panels and whole exome sequencing are the preferred and more efficient tools than single gene sequencing [6]. Gene panels may allow for the sequencing of hundreds of genes at once via next-generation sequencing, and their overall yield is between 15% and 25% in epileptic encephalopathies [14,18]. The number of genes included in gene panels ranges from 38 to 327, and whether including more genes would increase the yield of gene sequencing remains unclear, as 93% of genetically diagnosed patients were identified using 38-gene panels [19]. When whole exome sequencing is performed early in diagnostic evaluation in conjunction with trio-testing, diagnostic yield ranges from 20% to 40% [13,14,18].
CAUSATIVE GENES FOR DEES
Table 1 summarizes the phenotype MIM number, gene, location, inheritance, and protein function for DEEs. Several studies uncovered the pathogenic role of genetic variants involved in the synaptogenesis, pruning, neuronal migration and differentiation, neurotransmitter synthesis and release, structures, and functions of membrane receptors and transporters [20,21]. In a recent study of 41 infantile-onset DEE patients, the seven most frequent pathogenic or likely pathogenic variants were KCNQ2, STXBP1, CDKL5, SCN1A, KCNT1, SCN2A, and SCN8A [22]. In another study of 105 patients with epileptic encephalopathy who underwent genetic testing using the Illumina TruSight One panel, a diagnostic panel of 47 epileptic encephalopathy genes, 30 out of 105 patients (28.5%) were identified with pathogenic variants and likely pathogenic variants in ALDH7A1, CACNA1A, CDKL5, FOXG1, GABRB3, GRIN2A, KCNQ2, KCNQ3, PRRT2, SCN1A, SCN2A, SCN8A, SYNGAP1, UBE3A, and WWOX [23]. In another study of the 68 infants with epileptic encephalopathy, 13 patients (19%) were identified with pathogenic variants in 7 genes; SCN1A was the most frequently affected gene accounting for 38.5%, followed by STXBP1 (15.4%), CDKL5 (15.4%), KCNQ2 (15.4%), ARX (7.7%), and SCN8A (7.7%) [24].
Table 1.
Summary of genes and protein functions for developmental and epileptic encephalopathies
| Type | Phenotype MIM number | Gene | Location | Inheritance | Protein functiontance |
|---|---|---|---|---|---|
| DEE1 | 308350 | ARX | Xp21.3 | XLR | Transcriptional repressor and activator |
| DEE2 | 300672 | CDKL5 | Xp22.13 | XLD | Serine-threonine kinase |
| DEE3 | 609304 | SLC25A22 | 11p15.5 | AR | Transport of glutamate across the inner mitochondrial membrane |
| DEE4 | 612164 | STXBP1 | 9q34.11 | AD | Modulator of synaptic vesicle release |
| DEE5 | 613477 | SPTAN1 | 9q34.11 | AD | Cytoskeletal protein |
| DEE6 | 607208 | SCN1A | 2q24.3 | AD | Subunit of a voltage-gated sodium channel |
| DEE7 | 613720 | KCNQ2 | 20q13.33 | AD | Subunit of a voltage-gated potassium channel |
| DEE8 | 300607 | ARHGEF9 | Xq11.1 | XLR | Rho-like GTPase to regulate CDC42 and other genes |
| DEE9 | 300088 | PCDH19 | Xq22.1 | XL | calcium-dependent cell-adhesion protein |
| DEE10 | 613402 | PNKP | 19q13.33 | AR | Enzyme involved in DNA repair |
| DEE11 | 613721 | SCN2A | 2q24.3 | AD | Subunit of a voltage-gated sodium channel |
| DEE12 | 613722 | PLCB1 | 20p12.3 | AR | Mediates intracellular signaling downstream of G protein-coupled receptors and regulates the function of the endothelial barrier |
| DEE13 | 614558 | SCN8A | 12q13.13 | AD | Subunit of a voltage-gated sodium channel |
| DEE14 | 614959 | KCNT1 | 9q34.3 | AD | Subunit of a sodium-activated potassium channel |
| DEE15 | 615006 | ST3GAL3 | 1p34.1 | AR | Catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates |
| DEE16 | 615338 | TBC1D24 | 16p13.3 | AR | GTPase-activating protein for Rab family protein |
| DEE17 | 615473 | GNAO1 | 16q13 | AD | Modulators or transducers in various transmembrane signaling systems |
| DEE18 | 615476 | SZT2 | 1p34.2 | AR | Localized to the peroxisome, and is implicated in resistance to oxidative stress |
| DEE19 | 615744 | GABRA1 | 5q34 | AD | A component of the heteropentameric receptor for GABA |
| DEE20 | 300868 | PIGA | Xp22.2 | XLR | Catalytic subunit of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase complex |
| DEE21 | 615833 | NECAP1 | 12p13.31 | AR | Involved in endocytosis |
| DEE22 | 300896 | SLC35A2 | Xp11.23 | SMo, XLD | Transports nucleotide sugars from the cytosol into Golgi vesicles where glycosyltransferases function |
| DEE23 | 615859 | DOCK7 | 1p31.3 | AR | Functions as a guanine nucleotide exchange factor, which activates Rac1 and Rac3 Rho small GTPases by exchanging bound GDP for free GTP |
| DEE24 | 615871 | HCN1 | 5p12 | AD | Hyperpolarization-activated ion channel exhibiting weak selectivity for potassium over sodium ions |
| DEE25 | 615905 | SLC13A5 | 17p13.1 | AR | High-affinity sodium/citrate cotransporter that mediates citrate entry into cells and facilitate the synthesis of fatty acids and cholesterol |
| DEE26 | 616056 | KCNB1 | 20q13.13 | AD | Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain, but also in the pancreas and cardiovascular system |
| DEE27 | 616139 | GRIN2B | 12p13.1 | AD | Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium |
| DEE28 | 616211 | WWOX | 16q23.1-q23.2 | AR | Acts as a tumor suppressor and plays a role in apoptosis |
| DEE29 | 616339 | AARS1 | 16q22.1 | AR | Catalyzes the attachment of alanine to tRNA in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA |
| DEE30 | 616341 | SIK1 | 21q22.3 | AD | Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, gluconeogenesis and lipogenesis regulation, muscle growth and differentiation and tumor suppression |
| DEE31 | 616346 | DNM1 | 9q34.11 | AD | Microtubule-associated force-producing protein involved in producing microtubule bundles and able to bind and hydrolyze GTP |
| DEE32 | 616366 | KCNA2 | 1p13.3 | AD | Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the cardiovascular system |
| DEE33 | 616409 | EEF1A2 | 20q13.33 | AD | Promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis |
| DEE34 | 616645 | SLC12A5 | 20q13.12 | AR | Mediates electroneutral potassium-chloride cotransport in mature neurons and is required for neuronal Cl- homeostasis |
| DEE35 | 616647 | ITPA | 20p13 | AR | Pyrophosphatase that hydrolyzes the non-canonical purine nucleotides inosine triphosphate, deoxyinosine triphosphate as well as 2'-deoxy-N-6-hydroxylaminopurine triposphate and xanthosine 5'-triphosphate to their respective monophosphate derivatives |
| DEE36 | 300884 | ALG13 | Xq23 | XL | Multifunctional enzyme with both glycosyltransferase and deubiquitinase activities |
| DEE37 | 616981 | FRRS1L | 9q31.3 | AR | Important modulator of glutamate signaling pathway |
| DEE38 | 617020 | ARV1 | 1q42.2 | AR | Plays a role as a mediator in the endoplasmic reticulum cholesterol and bile acid homeostasis |
| DEE39 | 612949 | SLC25A12 | 2q31.1 | AR | Mitochondrial and calcium-binding carrier that catalyzes the calcium-dependent exchange of cytoplasmic glutamate with mitochondrial aspartate across the mitochondrial inner membrane |
| DEE40 | 617065 | GUF1 | 4p12 | AR | Promotes mitochondrial protein synthesis and may act as a fidelity factor of the translation reaction, by catalyzing a one-codon backward translocation of tRNAs on improperly translocated ribosomes |
| DEE41 | 617105 | SLC1A2 | 11p13 | AD | Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate |
| DEE42 | 617106 | CACNA1A | 19p13.13 | AD | Voltage-sensitive calcium channels that mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death |
| DEE43 | 617113 | GABRB3 | 15q12 | AD | Ligand-gated chloride channel which is a component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the brain |
| DEE44 | 617132 | UBA5 | 3q22.1 | AR | E1-like enzyme which specifically catalyzes the first step in ufmylation |
| DEE45 | 617153 | GABRB1 | 4p12 | AD | Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain |
| DEE46 | 617162 | GRIN2D | 19q13.33 | AD | Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium |
| DEE47 | 617166 | FGF12 | 3q28-q29 | AD | Involved in nervous system development and function and promotes neuronal excitability by elevating the voltage dependence of neuronal sodium channel SCN8A fast inactivation |
| DEE48 | 617276 | AP3B2 | 15q25.2 | AR | Subunit of non-clathrin- and clathrin-associated adaptor protein complex 3 that plays a role in protein sorting in the late-Golgi/trans-Golgi network and/or endosomes |
| DEE49 | 617281 | DENND5A | 11p15.4 | AR | Promotes the exchange of GDP to GTP, converting inactive GDP-bound Rab proteins into their active GTP-bound form |
| DEE50 | 616457 | CAD | 2p23.3 | AR | Encodes four enzymatic activities of the pyrimidine pathway (GATase, CPSase, ATCase and DHOase) |
| DEE51 | 617339 | MDH2 | 7q11.23 | AR | Malate dehydrogenase, mitochondrial |
| DEE52 | 617350 | SCN1B | 19q13.11 | AR | Regulatory subunit of multiple voltage-gated sodium channel complexes that play important roles in excitable membranes in brain, heart and skeletal muscle |
| DEE53 | 617389 | SYNJ1 | 21q22.11 | AR | Phosphatase that acts on various phosphoinositides, including phosphatidylinositol 4-phosphate, phosphatidylinositol (4,5)-bisphosphate and phosphatidylinositol (3,4,5)-trisphosphate |
| DEE54 | 617391 | HNRNPU | 1q44 | AD | DNA- and RNA-binding protein involved in several cellular processes such as nuclear chromatin organization, telomere-length regulation, transcription, mRNA alternative splicing and stability, Xist-mediated transcriptional silencing and mitotic cell progression |
| DEE55 | 617599 | PIGP | 21q22.13 | AR | Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis |
| DEE56 | 617665 | YWHAG | 7q11.23 | AD | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways |
| DEE57 | 617771 | KCNT2 | 1q31.3 | AD | Outward rectifying potassium channel which produces rapidly activating outward rectifier K+ currents |
| DEE58 | 617830 | NTRK2 | 9q21.33 | AD | Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity |
| DEE59 | 617904 | GABBR2 | 9q22.33 | AD | Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2 |
| DEE60 | 617929 | CNPY3 | 6p21.1 | AR | Toll-like receptor (TLR)-specific co-chaperone for HSP90B1. Required for proper TLR folding, except that of TLR3, and hence controls TLR exit from the endoplasmic reticulum |
| DEE61 | 617933 | ADAM22 | 7q21.12 | AR | Probable ligand for integrin in the brain, involved in regulation of cell adhesion and spreading and in inhibition of cell proliferation |
| DEE62 | 617938 | SCN3A | 2q24.3 | AD | Mediates the voltage-dependent sodium ion permeability of excitable membranes |
| DEE63 | 617976 | CPLX1 | 4p16.3 | AR | Positively regulates a late step in exocytosis of various cytoplasmic vesicles, such as synaptic vesicles and other secretory vesicles |
| DEE64 | 618004 | RHOBTB2 | 8p21.3 | AD | Interacts with the cullin-3 protein, a ubiquitin E3 ligase necessary for mitotic cell division |
| DEE65 | 618008 | CYFIP2 | 5q33.3 | AD | Involved in T-cell adhesion and p53/TP53-dependent induction of apoptosis |
| DEE66 | 618067 | PACS2 | 14q32.33 | AD | Multifunctional sorting protein that controls the endoplasmic reticulum (ER)-mitochondria communication, including the apposition of mitochondria with the ER and ER homeostasis |
| DEE67 | 618141 | CUX2 | 12q24.11-q24.12 | AD | Transcription factor involved in the control of neuronal proliferation and differentiation in the brain and regulates dendrite development and branching, dendritic spine formation, and synaptogenesis in cortical layers II-III |
| DEE68 | 618201 | TRAK1 | 3p22.1 | AR | Involved in the regulation of endosome-to-lysosome trafficking, including endocytic trafficking of EGF-EGFR complexes and GABA-A receptors |
| DEE69 | 618285 | CACNA1E | 1q25.3 | AD | Voltage-sensitive calcium channels mediate the entry of calcium ions into excitable cells |
| DEE70 | 618298 | PHACTR1 | 6p24.1 | AD | Binds actin monomers (G actin) and plays a role in multiple processes including the regulation of actin cytoskeleton dynamics, actin stress fibers formation, cell motility and survival, formation of tubules by endothelial cells, and regulation of PPP1CA activity |
| DEE71 | 618328 | GLS | 2q32.2 | AR | Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine and regulates the levels of the neurotransmitter glutamate, the main excitatory neurotransmitter in the brain |
| DEE72 | 618374 | NEUROD2 | 17q12 | AD | Critical factor essential for the repression of the genetic program for neuronal differentiation; prevents the formation of synaptic vesicle clustering at active zone to the presynaptic membrane in postmitotic neurons |
| DEE73 | 618379 | RNF13 | 3q25.1 | AD | Plays a role in cell proliferation, apoptosis regulation, and mediates ER stress-induced activation of JNK signaling pathway and apoptosis by promoting ERN1 activation and splicing of XBP1 mRNA |
| DEE74 | 618396 | GABRG2 | 5q34 | AD | Ligand-gated chloride channel which is a component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the brain |
| DEE75 | 618437 | PARS2 | 1p32.3 | AR | Encodes a putative member of the class II family of aminoacyl-tRNA synthetases and plays a critical role in protein biosynthesis by charging tRNAs with their cognate amino acids |
| DEE76 | 618468 | ACTL6B | 7q22.1 | AR | Involved in transcriptional activation and repression of select genes by chromatin remodeling |
| DEE77 | 618548 | PIGQ | 16p13.3 | AR | Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis |
| DEE78 | 618557 | GABRA2 | 4p12 | AR | Ligand-gated chloride channel which is a component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the brain |
| DEE79 | 618559 | GABRA5 | 15q12 | AD | Ligand-gated chloride channel subunit which is a component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the brain |
| DEE80 | 618580 | PIGB | 15q21.3 | AR | Involves in glycosylphosphatidylinositol-anchor biosynthesis and transfers the third alpha-1,2-mannose to Man2-GlcN-acyl-PI during GPI precursor assembly |
| DEE81 | 618663 | DMXL2 | 15q21.2 | AR | Serves as a scaffold protein for MADD and RAB3GA on synaptic vesicles and plays a role in the brain as a key controller of neuronal and endocrine homeostatic processes |
| DEE82 | 618721 | GOT2 | 16q21 | AR | Catalyzes the irreversible transamination of the L-tryptophan metabolite L-kynurenine to form kynurenic acid |
| DEE83 | 618744 | UGP2 | 2p15 | AR | Catalyzes the glucose-1-phosphate into UDP-glucose, a crucial precursor for the production of glycogen |
| DEE84 | 618792 | UGDH | 4p14 | AR | Catalyzes the formation of UDP-alpha-D-glucuronate, a constituent of complex glycosaminoglycans |
| DEE85 | 301044 | SMC1A | Xp11.22 | XLD | Involved in chromosome cohesion during cell cycle and in DNA repair |
| DEE86 | 618910 | DALRD3 | 3p21.31 | AR | A tRNA-binding protein that interacts with the methyltransferase METTL2 and facilitates METTL2-catalyzed m3C formation at position 32 in specific arginine tRNAs |
| DEE87 | 618916 | CDK19 | 6q21 | AD | In conjunction with its paralog CDK8 and other proteins, form a CDK module which regulates RNA polymerase II and transcriptional activity |
| DEE88 | 618959 | MDH1 | 2p15 | AR | Plays essential roles in the malate-aspartate shuttle and the tricarboxylic acid cycle, important in mitochondrial NADH supply for oxidative phosphorylation |
| DEE89 | 619124 | GAD1 | 2q31.1 | AR | Catalyzes the production of GABA |
| DEE90 | 301058 | FGF13 | Xq26.3-q27.1 | XLD | Microtubule-binding protein which directly binds tubulin and is involved in both polymerization and stabilization of microtubules |
AD, autosomal dominant; AR, autosomal recessive; XL, X-linked; XLD, X-linked dominant; XLR, X-linked recessive; SMo, somatic mosaicism.
ELECTROCLINICAL CHARACTERISTICS AND GENETIC ETIOLOGIES OF DEES
Ohtahara syndrome or early infantile epileptic encephalopathy with suppression-burst pattern is age-dependent epileptic encephalopathy that usually occurs within the first 3 months of age [20,25]. The most typical seizures are tonic spasms with or without series formation, although other seizure types can also be observed [20,26]. Electroencephalogram (EEG) shows a continuous suppression-burst pattern, higher-voltage bursts of slow waves mixed with multifocal spikes and alternate with isoelectric suppression phase in both waking and sleeping states [27]. Seizure patterns usually change with age, frequently evolve to West syndrome and further to Lennox-Gastaut syndrome [28]. The most frequent genetic abnormalities are found in STXBP1 (~30%), KCNQ2 (~20%), SCN2A (~10%); less common genetic variants are found in AARS, ARX, BRAT1, CACNA2D2, GNAO1, KCNT1, NECAP1, PIGA, PIGQ, SCN8A, SIK1, GABRA1, and SLC25A22 [29,30].
Early myoclonic encephalopathy
EME occurs within the first 3 months of age. Seizures are characterized by fragmentary myoclonic jerks which shift typically from one part of the body to another in a random, asynchronous pattern; other seizure types including tonic and focal seizures may also be observed [29-31]. Typical EEG shows a suppression-burst pattern like that seen in Ohtahara syndrome which becomes more prominent in sleep and may evolve to hypsarrhythmia in the middle to late infancy [25,32]. EME persists for long periods without evolution, except for the occasional transient phase of West syndrome, or changes into partial or severe epilepsy with multiple independent spike foci [25]. EME usually associated with inherited metabolic disorders, such as nonketotic hyperglycinemia, organic acidemias, Zellweger syndrome, and molybdenum cofactor deficiency [33]. In patients presenting as EME with negative metabolic workup, the most common genetic variants are found in ERBB4, PIGA, SETBP1, SIK1, and SLC25A22 [30].
Epilepsy of infancy with migrating focal seizures
EIMFS begins within the first 6 months of life. Migrating focal seizures occur usually in clusters lasting a few days followed by a few weeks or months of recovery. Seizures are very frequent within a cluster, and clusters increase in frequency within the first 2 years of life. EEG is usually normal at onset; spikes rapidly grow in frequency and develop multifocal within a few months. Multifocal spike-and-wave activities do not show any specific pattern and are not activated in sleep. The ictal EEG pattern is characterized by rhythmic monomorphic activity in the alpha-theta frequency range, although, spikes, and spike-waves can also be observed. It is common for an epileptic activity to remain limited to one region for a period of time and then progressively involve an adjacent area [34]. De novo KCNT1 variants (~50%) and SCN2A (~25%); less frequent genetic variants have been reported in PLCB1, QARS, SCN1A, SCN8A, SLC25A22, TBC1D24, and SLC12A5 [30,35-37].
Infantile spasms (West syndrome)
Infantile spasms or West syndrome is the most common epilepsy syndrome in infancy that usually starts in the first year of life, most frequently between the first 3 and 9 months of life. Infantile spasms represent a combination of the triad of infantile spasms, developmental deterioration, and hypsarrhythmic EEG pattern [38,39]. Seizures are characterized by brief symmetrical contractions of proximal and truncal muscles, which frequently occur in clusters [40,41]. Hypsarrhythmia, a typical interictal EEG pattern, consists of high amplitude, disorganized, and chaotic pattern with multifocal spikes and sharp wave discharges [29]. Ictal EEG activity includes a diffuse highamplitude triphasic slow wave, a low-amplitude brief fast discharge, or a short-lasting diffuse flattening of ongoing activity [42,43]. Genetic variants have been reported in CDKL5 (~10%), STXBP1 (~2%), ARX, GAMT, ALG13, SCN2A, SCN1A, ALG13, GABRB3, GNAO1, GRIN1, GRIN2A, GRIN2B, DNM1, DOCK7, FOXG1 (duplications), SCN8A, MAGI2, MEF2C, NEDDL4, NDP, NRXN1, ACADS, WDR45, PIGA, PLCB1, PTEN, SCA2, SCN1A, SETBP1, SIK1, SLC25A22, SLC35A2, SPTAN1, ST3Gal3, TBC1D24, TCF4, WWOX, and GABRA1 [30,44,45].
Dravet syndrome
Dravet syndrome is a severe epileptic encephalopathy, which begins in the first year of life in a previously healthy infant. Seizures are unilateral or generalized clonic or tonic-clonic, which are commonly prolonged and could be progressed into status epilepticus. Seizures are usually triggered by fever, immunization, or a hot environment but may also be afebrile [46]. During the second year of life, seizures no longer occur only when a child has a high temperature, and become more frequent, persistent, and often more lateralized [31]. EEG shows generalized focal and multifocal abnormalities, spikes, and spike-wave or polyspike-wave discharges, symmetric or not, predominate over the frontal and central areas, but occur over the temporal and occipital areas, too [47,48]. Channelopathy due to variants in the SCN1A gene encoding the alpha 1 subunit of the voltage-gated sodium (Nav1.1) channel has been reported in 90% of patients, with most de novo and missense variants. Less frequent genetic variants are found in PCDH19, GABRA1, GABRG2, HCN1, and STXBP1 [1,30,49]. SCN1A variants have been observed in a spectrum of febrile epilepsy syndromes, which ranges from genetic epilepsy with febrile seizures plus (GEFS+) to Dravet syndrome.
DISCUSSION
With shortened time and decrease in cost, next-generation sequencing has provided earlier diagnosis and earlier appropriate treatment in patients with DEEs, especially in those patients where clinical symptoms are not well-defined. Despite the increased genetic diagnostic yield, still, a considerable number of the patients remain undiagnosed. Medically intractable seizures and severe developmental delay are all the more frustrating when the genetic cause remains unknown. And thus, discovering the genetic etiology of DEEs has been the code to be deciphered for pediatric neurologists. Future directions to increase the diagnostic yield may include whole genome sequencing, targeted sequencing panels with singlemolecule molecular inversion probes (smMIP), and possibly brain tissue transcriptome analysis with total RNA sequencing. Identification of further genes and novel pathways will provide a clear picture to families and caregivers and may also help in the development of target-specific therapies in DEEs.